Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review.

In 30 seconds

This systematic review evaluated 96 studies on frontline therapies for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). The review found that nearly half of patients relapsed within 3 years, with overall survival rates of 49%-69%. Blinatumomab showed significant efficacy, reducing the risk of death by 59% compared to chemotherapy alone in minimal residual disease negative patients.

Key findings

• Nearly half of patients relapsed within 3 years of frontline chemotherapy.
• Overall survival rates ranged from 49% to 69% beyond 3 years.
• Blinatumomab reduced the risk of death by 59% compared to chemotherapy alone.
• Median overall survival reached 41.2 months with blinatumomab monotherapy in MRD-positive patients.

Why it matters

The findings highlight the poor prognosis associated with frontline chemotherapy for Ph- B-ALL and underscore the potential of targeted therapies like blinatumomab to improve outcomes in this patient population.